Maternal type 1 diabetes causes heart defects.

Published Date: 02 Mar 2023

A review of more than 600,000 Finnish births from 2006 to 2016 found that mothers with type 1 diabetes had more than four times as many children born with heart defects.

Read Full News

Latest News

3-Year BE HEARD Data Link Bimekizumab to Fewer HS Draining Tunnels

3-Year BE HEARD Data Link Bimekizumab to Fewer HS Draining Tunnels

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Examining Topical Therapy for Atopic Dermatitis: Clinical Forum Perspectives

Examining Topical Therapy for Atopic Dermatitis: Clinical Forum Perspectives

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD Amit Garg, MD

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Todays Updates

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk Louie Pasculli

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy Isabella Ciccone, MPH

Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.

Todays Updates

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk Louie Pasculli

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy Isabella Ciccone, MPH

Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.

Latest News

3-Year BE HEARD Data Link Bimekizumab to Fewer HS Draining Tunnels

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Examining Topical Therapy for Atopic Dermatitis: Clinical Forum Perspectives

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

News All Time

From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class Linda Stein Gold, MD, Andrew Blauvelt, MD

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD Eric Simpson, MD, MCR

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD Aaron R. Mangold, MD

Aaron Mangold, MD, discusses phase 2 BEACON data on brepocitinib, a TYK2/JAK1 inhibitor, in cutaneous sarcoidosis presented at EADV 2026.

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

EADV Congress 2026: 9 Late Breakers to Know

EADV Congress 2026: 9 Late Breakers to Know

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Advances in Treating High-Impact Psoriasis from EADV 2026 Christopher G. Bunick, MD, PhD

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Recommended News For You

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

More Data Back Teclistamab for Autoimmune Disease

Induction Immunotherapy Has Durable Survival Benefit in LACC

Global inequalities found in cancer research funding

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

No Cellphone, Brain Cancer Link; Testosterone Paradox; Breast Density and Cancer

Recommended Articles For You

Community-Based Cancer Prevention Through Environmental Risk Mapping 

Electronic Blood-Product Inventory Networks: Clinical Governance, Interoperability, and Patient-Safety Implications 

Bone Marrow Microenvironment Remodeling in Hematologic Disorders 

Targeting the Tumor Microenvironment: Next-Generation Strategies for Immuno-Oncology Success 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Transforming Perioperative MIBC Care in Community Practice: Navigating Emerging Data, Guideline Changes, and Adverse Event Management Protocols

2.

Coffee and tea linked to lower head and neck cancer risk

3.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

4.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

5.

Ranking of the Best US Hospitals for Psychiatric Care.

1.

Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology

2.

Surgical Innovation Through Bone Marrow–Reserving Surgical Strategies

3.

Ultimate Guide to Oncology Services in the USA

4.

Understanding Granulosa Cell Tumors: Symptoms, Diagnosis, and Treatments"

5.

Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Understanding the causes of anemia in adults beyond nutritional deficiencies

2.

From Guidelines to Practice: Hematology

3.

How Advances in Cancer Research Are Improving Treatment Options

4.

Understanding Platelet Disorders

5.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot